We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment (RIAT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00258921
First Posted: November 28, 2005
Last Update Posted: November 22, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Bristol-Myers Squibb
Information provided by:
Sanofi
  Purpose
To support physicians in their active management of hypertensive patients. By targeting specific systolic and diastolic blood pressure (BP) figures physicians will closely monitor the BP values and as such will have an individualized control of the treatment in each patient.

Condition
Hypertension

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An International Registry in Essential Hypertension

Further study details as provided by Sanofi:

Estimated Enrollment: 31870
Study Start Date: March 2004
Study Completion Date: July 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Main criteria are listed hereafter:

Inclusion Criteria:

  • Adult hypertensive
  • Either newly diagnosed and untreated
  • or previously treated and uncontrolled Patients of both sexes with essential hypertension

Exclusion Criteria:

  • Known secondary hypertension
  • Known secondary curable hypertension (i.e. pheochromocytoma, aldosterone producing adenoma, Cushing disease). Patients with renal disease are not excluded.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00258921


Sponsors and Collaborators
Sanofi
Bristol-Myers Squibb
Investigators
Study Director: Pascale BLONDIN, MD Sanofi
  More Information

ClinicalTrials.gov Identifier: NCT00258921     History of Changes
Other Study ID Numbers: R-9511
First Submitted: November 24, 2005
First Posted: November 28, 2005
Last Update Posted: November 22, 2007
Last Verified: November 2007

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases